Unlike other iron formulations that contain an iron core surrounded by a layer of carbohydrate, Monoferric utilizes a dynamic matrix of alternating iron and carbohydrate layers1,2
This description reflects structural chemistry only and does not imply differences in clinical efficacy, safety, or tolerability.
Sign up to contact a representative and receive information about Monoferric.
The safety and efficacy of Monoferric for treatment of IDA were evaluated in two randomized, open-label, noninferiority, actively controlled clinical trials performed in a total of 3050 patients with IDA of different etiologies.2,6
Complete IV iron replacement in as little as 20 minutes4,a
| a | Intravenous infusion over at least 20 minutes. Repeat dose if IDA reoccurs. |
Monoferric patient profiles
Do you see any of these types of patients in your practice? See why Monoferric was right for them.
IDA=iron deficiency anemia.
References: 1. Auerbach M, Macdougall I. Hemodial Int. 2017;21:S83–S92. 2. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. Am J Hematol. 2019;94(9):1007‐1014. 3. Kalra PA, Bhandari S. Int J Nephrol Renovasc Dis. 2016;9:53‐64. 4. Monoferric (ferric derisomaltose) Prescribing Information; Pharmacosmos Therapeutics Inc., Morristown, NJ: 2022. 5. Jahn MR, Andreasen HB, Fütterer S, et al. Eur J Pharm Biopharm. 2011;78(3):480‐491. 6. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Nephrol Dial Transplant. 2021;36(1):111-120.